Present TJ004309 Phase 1 results
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 25 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- June 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Data presentation on TJ004309 Phase 1 results in 1H 2021.”
What we found
Evidence strength A What the grades mean
Filings state that TJ004309 Phase 1 data were presented at the ASCO 2021 virtual meeting in June 2021, within the 1H 2021 deadline.
-
A Tracon Pharmaceuticals, Inc. 8-K filed 2021-08-11
“In June, we presented preliminary Phase 1 data for the CD73 antibody uliledlimab (TJ4309) at the 2021 ASCO virtual annual meeting.” ✓ confirmed on the page
-
A Tracon Pharmaceuticals, Inc. 10-Q filed 2021-08-11
“in June 2021 we presented data from the ongoing Phase 1 trial at the ASCO 2021 virtual meeting” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Present
- Deliverable
- TJ004309 Phase 1 results data presentation
- In the company’s control
- High
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Tracon Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C394319-024651 · Corrections policy